412,470 Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by First Trust Advisors LP

Vertex Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • First Trust Advisors increased its Vertex Pharmaceuticals stake by 142.6% in the third quarter, purchasing 412,470 shares and bringing its holdings to 701,649 shares, valued at about $366.8 million.
  • Analyst sentiment is broadly positive: 25 analysts rate VRTX a Buy and one a Strong Buy, with a consensus “Moderate Buy” rating and an average price target of $596.44.
  • Vertex reported quarterly revenue of $3.44 billion, above expectations and up 11.8% year over year, but earnings per share of $4.76 narrowly missed the $4.82 consensus estimate.
  • Interested in Vertex Pharmaceuticals? Here are five stocks we like better.

First Trust Advisors LP boosted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 142.6% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 701,649 shares of the pharmaceutical company's stock after buying an additional 412,470 shares during the quarter. First Trust Advisors LP owned approximately 0.28% of Vertex Pharmaceuticals worth $366,829,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. BNP Paribas boosted its holdings in shares of Vertex Pharmaceuticals by 8.7% during the third quarter. BNP Paribas now owns 4,350 shares of the pharmaceutical company's stock worth $2,275,000 after purchasing an additional 348 shares during the period. State Street Corp lifted its holdings in Vertex Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 12,024,456 shares of the pharmaceutical company's stock worth $6,286,506,000 after buying an additional 152,997 shares during the period. Ilmarinen Mutual Pension Insurance Co lifted its holdings in Vertex Pharmaceuticals by 22.8% in the 3rd quarter. Ilmarinen Mutual Pension Insurance Co now owns 41,500 shares of the pharmaceutical company's stock worth $21,697,000 after buying an additional 7,700 shares during the period. E Fund Management Hong Kong Co. Ltd. grew its position in shares of Vertex Pharmaceuticals by 51.7% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 2,250 shares of the pharmaceutical company's stock worth $1,176,000 after buying an additional 767 shares during the last quarter. Finally, Rathbones Group PLC grew its position in shares of Vertex Pharmaceuticals by 3.7% in the 3rd quarter. Rathbones Group PLC now owns 1,083 shares of the pharmaceutical company's stock worth $566,000 after buying an additional 39 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company's stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, Director Sangeeta Bhatia sold 271 shares of the company's stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $547.86, for a total value of $148,470.06. Following the sale, the director directly owned 4,653 shares of the company's stock, valued at $2,549,192.58. This represents a 5.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy Thornberry sold 1,000 shares of the company's stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $547.86, for a total transaction of $547,860.00. Following the completion of the sale, the director directly owned 1,109 shares in the company, valued at $607,576.74. This represents a 47.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 16,557 shares of company stock valued at $9,071,071. 0.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on VRTX shares. Wells Fargo & Company upped their target price on Vertex Pharmaceuticals from $550.00 to $650.00 and gave the company an "overweight" rating in a report on Tuesday, November 3rd. Sanford C. Bernstein upgraded shares of Vertex Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, July 29th. Barclays boosted their price objective on shares of Vertex Pharmaceuticals from $617.00 to $626.00 and gave the company an "overweight" rating in a research report on Wednesday, November 4th. Canaccord Genuity Group boosted their price objective on shares of Vertex Pharmaceuticals from $436.00 to $442.00 and gave the company a "hold" rating in a research report on Tuesday, August 4th. Finally, Rothschild & Co Redburn upped their price objective on shares of Vertex Pharmaceuticals from $570.00 to $580.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, Vertex Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $596.44.

Get Our Latest Stock Report on VRTX

Vertex Pharmaceuticals Trading Down 1.1%

VRTX opened at $514.75 on Friday. The stock has a market cap of $130.51 billion, a PE ratio of 33.12, a PEG ratio of 2.73 and a beta of 0.28. The company has a quick ratio of 1.89, a current ratio of 2.34 and a debt-to-equity ratio of 0.17. The business has a 50 day moving average of $522.72 and a 200-day moving average of $485.26. Vertex Pharmaceuticals Incorporated has a 52 week low of $412.27 and a 52 week high of $568.67.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.06). The firm had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.42 billion. Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 21.98%. The company's revenue for the quarter was up 11.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $4.80 earnings per share. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 16.10 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Company Profile

(Free Report)

Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex's CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.

Read More

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?

Before you consider Vertex Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.

While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines